BridgeBio Pharma Inc (BBIO) — Tangible Net Worth Ratio

Latest as of December 2020: 100.0%

BridgeBio Pharma Inc (BBIO) has a Tangible Net Worth Ratio of 100.0% as of December 2020. This metric is calculated by deducting intangible assets ($0.00) from net assets ($107.89 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See BridgeBio Pharma Inc book value and equity for net asset value and shareholders' equity analysis.

Tangible NW Ratio

100.0%
Tangible equity / total equity

Net Assets (Equity)

$107.89 Million
USD

Intangible Assets

$0.00
Goodwill, patents, brand value

Total Assets

$703.59 Million
USD

BridgeBio Pharma Inc Tangible Net Worth Ratio (2019–2020)

This chart shows how BridgeBio Pharma Inc's Tangible Net Worth Ratio has changed across 2 annual periods from 2019 to 2020. As of December 2020, the ratio stands at 100.0%, reflecting net assets of $107.89 Million with intangible assets of $0.00 USD. Also explore BBIO year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Annual Tangible Net Worth Ratio for BridgeBio Pharma Inc (2019–2020)

The table below presents the year-by-year Tangible Net Worth Ratio for BridgeBio Pharma Inc from 2019 to 2020, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see how much is BridgeBio Pharma Inc worth.

Year Tangible NW Ratio Net Assets (USD) Intangible Assets Total Assets Change (pp)
2020 100.0% $107.89 Million $0.00 $703.59 Million ▲ +0.0 pp
2019 100.0% $475.98 Million $0.00 $631.68 Million
pp = percentage points